ArticleJournal of medicinal chemistry2026
Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Luca LizzadroDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Jiapeng LiDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0003-4321-1150
Taha Y TahaGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, California 94158, United States.ORCID 0000-0002-7344-7490
Gilles DegotteDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Tyler C DetomasiDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0003-4390-108X
Francisco J Zapatero-BelinchonGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, California 94158, United States.ORCID 0000-0002-2751-8411
Eric R HantzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-2588-7619
Sijie HuangDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Yusuke MatsuiGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, California 94158, United States.
Will R HendersonDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0003-4791-3184
Jack T McCannDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-8812-829X
Mauricio MontanoGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, California 94158, United States.
Julia RosecransGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, California 94158, United States.
Daniel F Torres PomaresDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Briana L McGovernDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-0492-9904
Randy Diaz-TapiaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Jared BenjaminDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Mary E GordonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Isidora D SuazoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Nicholas S SettineriAdvanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.ORCID 0000-0003-0272-454X
Amy DialloDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Nevan J KroganDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0003-4902-337X
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-6098-7367
Kliment A VerbaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Randy AlbrechtDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Kris M WhiteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0003-0889-0506
Melanie OttGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, California 94158, United States.
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0001-7704-9185
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-1240-2846
Funding
Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4MStrengthening the ISMMS research and response capabilities for pathogens of pandemic potentialG20AI174733 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ALBRECHT, RANDY A. · 2022 to 2022
$2.3MNIAID NIH HHS G20 AI174733NIAID NIH HHS U19 AI171110
Abstract
The main proteases (M
Indexed as
Antiviral AgentsBrainCoronavirus 3C ProteasesCOVID-19 Drug TreatmentMiddle East Respiratory Syndrome CoronavirusProtease InhibitorsSARS-CoV-2Administration, OralAnimalsCOVID-19Disease Models, AnimalDogsDrug DiscoveryHumansMaleMiceAntiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.